Post Marketing Surveillance Study of Cuprimine

Expanded access is no longer available for this treatment.
Sponsor:
Information provided by (Responsible Party):
Merck Sharp & Dohme Corp.
ClinicalTrials.gov Identifier:
NCT01374282
First received: June 14, 2011
Last updated: April 1, 2014
Last verified: April 2014
  Purpose

Cuprimine (penicillamine) was made available in the Philippines by the Sponsor under a Compassionate Special Permit issued by the Bureau of Food and Drugs. Physicians were able to request the drug for their patients from the Sponsor. A Clinical Study Report form was completed for each purchase of Cuprimine.


Condition Intervention
Scleroderma
Drug: Cuprimine (penicillamine)

Study Type: Expanded Access     What is Expanded Access?
Official Title: Post Marketing Surveillance Study of Cuprimine (MK-0172-001)

Resource links provided by NLM:


Further study details as provided by Merck Sharp & Dohme Corp.:

Intervention Details:
    Drug: Cuprimine (penicillamine)
    Dosage determined by the physician based on indication for treatment
  Eligibility

Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

- None

Exclusion Criteria:

- None

  Contacts and Locations
No Contacts or Locations Provided
  More Information

No publications provided

Responsible Party: Merck Sharp & Dohme Corp.
ClinicalTrials.gov Identifier: NCT01374282     History of Changes
Other Study ID Numbers: 0172-001
Study First Received: June 14, 2011
Last Updated: April 1, 2014
Health Authority: Philippines: Bureau of Food and Drugs

Additional relevant MeSH terms:
Scleroderma, Systemic
Scleroderma, Diffuse
Connective Tissue Diseases
Skin Diseases
Penicillamine
Antidotes
Protective Agents
Physiological Effects of Drugs
Pharmacologic Actions
Antirheumatic Agents
Therapeutic Uses
Chelating Agents
Molecular Mechanisms of Pharmacological Action

ClinicalTrials.gov processed this record on April 14, 2014